Imatinib for the treatment of rheumatic diseases.
Paniagua
Ricardo T
RT
Division of Immunology and Rheumatology at Stanford University School of Medicine, Stanford, USA.
Robinson
William H
WH
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy; D001549:Benzamides; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000188:drug therapy*
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate